Compare · CRXT vs NVO
CRXT vs NVO
Side-by-side comparison of Clarus Therapeutics Holdings Inc. (CRXT) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CRXT and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $220.35B, about 6844.3x CRXT ($32.2M).
- NVO has hit the wire 5 times in the past 4 weeks while CRXT has been quiet.
- NVO has more recent analyst coverage (25 ratings vs 3 for CRXT).
- Company
- Clarus Therapeutics Holdings Inc.
- Novo Nordisk A/S
- Price
- $0.10-33.17%
- $41.18+6.93%
- Market cap
- $32.2M
- $220.35B
- 1M return
- -
- +13.32%
- 1Y return
- -
- -34.24%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2021
- News (4w)
- 0
- 5
- Recent ratings
- 3
- 25
Clarus Therapeutics Holdings Inc.
Clarus Therapeutics Holdings, Inc. operates as a men's health specialty pharmaceutical company that focuses on the development and commercialization of oral testosterone replacement therapy in the United States. It offers JATENZO, a soft gel oral formulation of testosterone undecanoate for treating hypogonadal men. The company has a licensing agreement with HavaH Therapeutics for product to treat androgen-dependent inflammatory breast disease and certain forms of breast cancer. Clarus Therapeutics Holdings, Inc. was founded in 2003 and is based in Northbrook, Illinois.
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest CRXT
- SEC Form 15-12G filed by Clarus Therapeutics Holdings Inc.
- Clarus Therapeutics Holdings Inc. filed SEC Form 8-K: Bankruptcy or Receivership, Completion of Acquisition or Disposition of Assets, Material Modification to Rights of Security Holders, Changes in Control of Registrant, Leadership Update, Other Events
- SEC Form S-8 POS filed by Clarus Therapeutics Holdings Inc.
- SEC Form POS AM filed by Clarus Therapeutics Holdings Inc.
- SEC Form POS AM filed by Clarus Therapeutics Holdings Inc.
- SEC Form POS AM filed by Clarus Therapeutics Holdings Inc.
- SEC Form POS AM filed by Clarus Therapeutics Holdings Inc.
- Clarus Therapeutics Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- SEC Form SC 13G/A filed by Clarus Therapeutics Holdings Inc. (Amendment)
- Clarus Therapeutics Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
Latest NVO
- The Longevity Trade Is No Longer a Buzzword — It's a $120 Billion Market, and the FDA Just Cleared the First Cellular Rejuvenation Trial
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Wolfe Research initiated coverage on Novo Nordisk A/S